Compare Gilead Sciences, Inc. (GILD) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Northrop Grumman Corporation — how do they compare? Gilead Sciences, Inc. trades at $133.02 (market cap $163.51B), while Northrop Grumman Corporation trades at $526.11 (market cap $74.60B). The key difference: Gilead Sciences, Inc. is far larger — about 2.2× Northrop Grumman Corporation's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | NOC | |
|---|---|---|
Market Cap | $163.51B | $74.60B |
Sector | Health | Industrials |
52-Week High | $155.80 | $768.02 |
52-Week Low | $108.22 | $496.02 |
Enterprise Value | $178.05B | $88.82B |
Dividend Yield | 2.49% | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Northrop Grumman (NOC) trades at $528.67, down 2.43% amid broader defense sector weakness. The stock shows strong fundamentals with consistent earnings beats, a 10.8% net margin, and $95.6B backlog supporting revenue visibility. Technical indicators signal bearish momentum with price near support at $523, while RSI at 24 suggests potential oversold conditions. Recent news highlights expansion in missile defense and space systems amid increased NATO spending expectations.
NOC presents a compelling value opportunity with 57% analyst buy ratings and $655 price target implying 24% upside. Key catalysts include Q2 earnings beat potential and defense budget tailwinds, though political uncertainty and execution risks on large contracts remain concerns. The stock's 16.5 P/E ratio appears attractive relative to historical averages given its earnings growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
